Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates

被引:21
作者
Bandyopadhyaya, AK
Johnsamuel, J
Al-Madhoun, AS
Eriksson, S
Tjarks, W [1 ]
机构
[1] Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA
[2] Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, Sect Vet Med Chem, SE-75123 Uppsala, Sweden
关键词
3D-QSAR; CoMFA; CoMSIA; thymidine kinase 1 (TK1); TK1; substrates;
D O I
10.1016/j.bmc.2004.12.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thymidine kinase 1 (TK1) is a key target for antiviral and anticancer chemotherapy. Three-dimensional quantitative structure-activity relationship (3D-QSAR) using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques was applied to analyze the phosphorylation capacity of a series of 31 TK1 substrates. The optimal predictive CoMFA model with 26 molecules provided the following values: cross-validated r(2) (q(2)) = 0.651, non-cross-validated r(2) = 0.980, standard error of estimate (s) = 0.207, F = 129.3. For the optimal CoMSIA model the following values were found: q(2) = 0.619, r(2) = 0.994, s = 0.104, F = 372.2. The CoMSIA model includes steric, electrostatic, and hydrogen bond donor fields. The predictive capacity of both models was successfully validated by calculating known phosphorylation rates of five TK1 substrates that were not included in the training set. Contour maps obtained from CoMFA and CoMSIA models correlated with the experimentally developed SAR. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1681 / 1689
页数:9
相关论文
共 45 条
[1]  
Al-Madhoun AS, 2004, MINI-REV MED CHEM, V4, P341
[2]   Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy [J].
Al-Madhoun, AS ;
Johnsamuel, J ;
Barth, RF ;
Tjarks, W ;
Eriksson, S .
CANCER RESEARCH, 2004, 64 (17) :6280-6286
[3]   Synthesis of a small library of 3-(Carboranylalkyl)thymidines and their biological evaluation as substrates for human thymidine kinases 1 and 2 [J].
Al-Madhoun, AS ;
Johnsamuel, J ;
Yan, JH ;
Ji, WH ;
Wang, JH ;
Zhuo, JC ;
Lunato, AJ ;
Woollard, JE ;
Hawk, AE ;
Cosquer, GY ;
Blue, TE ;
Eriksson, S ;
Tjarks, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :4018-4028
[4]   MAMMALIAN DEOXYRIBONUCLEOSIDE KINASES [J].
ARNER, ESJ ;
ERIKSSON, S .
PHARMACOLOGY & THERAPEUTICS, 1995, 67 (02) :155-186
[5]   Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors [J].
Barth, RF ;
Yang, WL ;
Al-Madhoun, AS ;
Johnsamuel, J ;
Byun, Y ;
Chandra, S ;
Smith, DR ;
Tjarks, W ;
Eriksson, S .
CANCER RESEARCH, 2004, 64 (17) :6287-6295
[6]   3D-QSAR CoMFA/CoMSIA studies on urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents [J].
Bhongade, BA ;
Gadad, AK .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (10) :2797-2805
[7]   Crystal structure of varicella zoster virus thymidine kinase [J].
Bird, LE ;
Ren, J ;
Wright, A ;
Leslie, KD ;
Degrève, B ;
Balzarini, J ;
Stammers, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (27) :24680-24687
[8]   Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients [J].
Broët, P ;
Romain, S ;
Daver, A ;
Ricolleau, G ;
Quillien, V ;
Rallet, A ;
Asselain, B ;
Martin, PM ;
Spyratos, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2778-2787
[9]   SAMPLE-DISTANCE PARTIAL LEAST-SQUARES - PLS OPTIMIZED FOR MANY VARIABLES, WITH APPLICATION TO COMFA [J].
BUSH, BL ;
NACHBAR, RB .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1993, 7 (05) :587-619
[10]   The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position [J].
Byun, Y ;
Yan, J ;
Al-Madhoun, AS ;
Johnsamuel, J ;
Yang, WL ;
Barth, RF ;
Staffan, E ;
Tjarks, W .
APPLIED RADIATION AND ISOTOPES, 2004, 61 (05) :1125-1130